查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1703269

非臨床試驗市場－全球產業規模、佔有率、趨勢、機會和預測，按研究類型、按測試、按治療領域、按最終用戶、按地區和競爭進行細分，2020 年至 2030 年

Non-Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Study Type, By Test, By Therapeutic Area, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 187 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球非臨床試驗市場價值為 113.6 億美元，預計到 2030 年將達到 169.5 億美元，複合年成長率為 6.87%。全球非臨床試驗市場是製藥和醫療保健產業中一個充滿活力且不可或缺的組成部分，在新藥和醫療器材的開發和批准中發揮關鍵作用。這個市場涵蓋了在人類身上測試潛在治療或療法之前發生的廣泛活動。非臨床試驗，通常稱為臨床前試驗，涉及對動物、體外系統或電腦模擬進行的一系列嚴格測試和評估，以評估實驗藥物和醫療產品的安全性、有效性和毒性。全球非臨床試驗市場成長的主要驅動力之一是針對各種健康狀況和疾病的創新藥品和醫療設備的需求不斷成長。因此，製藥和生物技術公司以及學術研究機構在非臨床試驗方面投入了大量資金，以確保其產品符合監管標準並且對人類使用安全。這導致非臨床試驗服務外包給專門合約研究組織（CRO）的數量激增，進一步推動了市場擴張。

市場概覽
預測期 2026-2030
2024年市場規模 113.6億美元
2030年市場規模 169.5億美元
2025-2030 年複合年成長率 6.87%
成長最快的領域 製藥和生物技術公司
最大的市場 北美洲

關鍵市場促進因素

對創新藥品和醫療器材的需求不斷成長

主要市場挑戰

嚴格的監理合規性

主要市場趨勢

創新療法的興起

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：全球非臨床試驗市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依研究類型（藥效學 (PD) 研究、藥物動力學 (PK) 研究、毒理學研究）
    • 通過測試（電腦模擬、體外、體內）
    • 依治療領域（腫瘤學、心血管病學、神經病學、免疫學、其他）
    • 按最終用戶（製藥和生物技術公司、合約研究組織 (CRO)、學術和政府研究機構、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖
    • 按學習類型
    • 通過測試
    • 按治療領域
    • 按最終用戶
    • 按地區

第5章：亞太非臨床試驗市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按學習類型
    • 通過測試
    • 按治療領域
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第6章：歐洲非臨床試驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第7章：北美非臨床試驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
    • 學習類型
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第8章：南美洲非臨床試驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第9章：中東和非洲非臨床試驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章：市場動態

  • 驅動程式
  • 挑戰

第 11 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 12 章：全球非臨床試驗市場：SWOT 分析

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Labcorp Drug Development
  • Charles River Laboratories
  • PPD (Pharmaceutical Product Development)
  • ICON plc
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca plc
  • CMIC HOLDINGS Co., LTD
  • ProPharma
  • MorphoSys AG

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 16882

Global Non-Clinical Trials Market was valued at USD 11.36 Billion in 2024 and is expected to reach USD 16.95 Billion in the forecast period with a CAGR of 6.87% through 2030. The Global Non-Clinical Trials Market represents a dynamic and essential component of the pharmaceutical and healthcare industries, playing a pivotal role in the development and approval of new drugs and medical devices. This market encompasses a wide range of activities that occur before a potential treatment or therapy is tested on human subjects. Non-clinical trials, often referred to as preclinical trials, involve a series of rigorous tests and evaluations conducted on animals, in vitro systems, or computer simulations to assess the safety, efficacy, and toxicity of experimental drugs and medical products. One of the key drivers behind the growth of the global non-clinical trials market is the ever-increasing demand for innovative pharmaceuticals and medical devices to address a myriad of health conditions and diseases. As a result, pharmaceutical and biotechnology companies, as well as academic research institutions, are heavily invested in non-clinical trials to ensure that their products meet regulatory standards and are safe for human use. This has led to a surge in the outsourcing of non-clinical trial services to specialized contract research organizations (CROs), further fueling market expansion.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 11.36 Billion
Market Size 2030USD 16.95 Billion
CAGR 2025-20306.87%
Fastest Growing SegmentPharmaceutical and Biotechnology Companies
Largest MarketNorth America

Key Market Drivers

Rising Demand for Innovative Pharmaceuticals and Medical Devices

The global demand for innovative pharmaceuticals and medical devices is a primary driver behind the robust growth of the Global Non-Clinical Trials Market. As the global population ages and the prevalence of chronic diseases continues to escalate, there is an increasing need for cutting-edge therapies and medical solutions. This burgeoning demand has propelled pharmaceutical and biotechnology companies, as well as academic research institutions, into an intense race to develop new drugs and devices that address a wide spectrum of health conditions.

Non-clinical trials, also known as preclinical trials, are instrumental in meeting this demand by providing a crucial testing ground for these innovative products before they advance to human clinical trials. These trials involve comprehensive assessments of safety, efficacy, and toxicity, which are essential for regulatory approval and eventual market access. In 2023, research and development spending in the pharmaceutical industry exceeded USD 300 billion globally, highlighting the industry's commitment to innovation and the critical role of non-clinical trials in the drug development process.

Key Market Challenges

Stringent Regulatory Compliance

Complex and Evolving Regulations: Regulatory agencies, such as the FDA in the United States and the EMA in Europe, have developed comprehensive guidelines that govern non-clinical trials. However, these regulations are intricate, subject to frequent updates, and can vary from one region to another. Navigating this complex regulatory landscape demands substantial expertise and resources, which can slow down the initiation and progression of non-clinical trials. Stringent Data and Documentation Requirements: Regulatory authorities require extensive documentation and data to support non-clinical trial submissions. Researchers must meticulously document every aspect of the trial, from study design and procedures to results and statistical analyses. This demanding documentation process can be time-consuming and resource-intensive, diverting valuable time and resources away from research activities.

Ethical and Patient Safety Considerations: Regulatory compliance often entails rigorous ethical considerations and a focus on patient safety. These ethical standards necessitate adherence to guidelines that protect the welfare of research subjects, whether they are animals or humans. Ensuring compliance with these ethical standards can lead to additional hurdles and delays, particularly when addressing the safety and well-being of trial participants. Meeting regulatory compliance requirements is resource-intensive. Companies and research organizations must invest in state-of-the-art facilities, skilled personnel, and advanced technologies to conduct non-clinical trials that satisfy regulatory standards.

Key Market Trends

Rise in Innovative Therapies

The Global Non-Clinical Trials Market is experiencing a substantial boost due to the relentless rise in demand for innovative therapies. As the global population grapples with an increasing burden of diseases, there has been an unmistakable call for transformative pharmaceuticals and medical devices to address these health challenges. This insatiable demand for groundbreaking treatments has spurred pharmaceutical and biotechnology companies, as well as academic research institutions, to intensify their research and development efforts. Consequently, non-clinical trials have taken center stage as a pivotal phase in the development of these innovative therapies.

In the current landscape, innovative therapies encompass a wide spectrum of cutting-edge approaches, including precision medicine, gene therapies, immunotherapies, and targeted therapeutics, among others. These novel treatments hold the promise of offering highly effective and personalized solutions for a range of health conditions, from rare genetic disorders to complex cancers. However, before these therapies can advance to human clinical trials and eventually reach patients, they must undergo rigorous assessment in non-clinical trials.

Key Market Players

  • Labcorp Drug Development
  • Charles River Laboratories
  • PPD (Pharmaceutical Product Development)
  • ICON plc
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca plc
  • Cmic Holdings Co., Ltd
  • ProPharma
  • MorphoSys AG

Report Scope:

In this report, the Global Non-Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Clinical Trials Market, By Study Type:

  • Pharmacodynamics (PD) studies
  • Pharmacokinetics (PK) studies
  • Toxicology studies

Non-Clinical Trials Market, By Test:

  • In silico
  • In vitro
  • In vivo

Non-Clinical Trials Market, By Therapeutic Area:

  • Oncology
  • Cardiovascular
  • Neurology
  • Immunology
  • Others

Non-Clinical Trials Market, By End User:

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic and Government Research Institutes
  • Others

Non-Clinical Trials Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Clinical Trials Market.

Available Customizations:

Global Non-Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Non-Clinical Trials Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Study Type (Pharmacodynamics (PD) studies, Pharmacokinetics (PK) studies, Toxicology studies)
    • 4.2.2. By Test (In silico, In vitro, In vivo )
    • 4.2.3. By Therapeutic Area (Oncology, Cardiovascular, Neurology, Immunology, Others)
    • 4.2.4. By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Academic and Government Research Institutes, Others )
    • 4.2.5. By Region
    • 4.2.6. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Study Type
    • 4.3.2. By Test
    • 4.3.3. By Therapeutic Area
    • 4.3.4. By End User
    • 4.3.5. By Region

5. Asia Pacific Non-Clinical Trials Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Study Type
    • 5.2.2. By Test
    • 5.2.3. By Therapeutic Area
    • 5.2.4. By End User
    • 5.2.5. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Non-Clinical Trials Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Study Type
        • 5.3.1.2.2. By Test
        • 5.3.1.2.3. By Therapeutic Area
        • 5.3.1.2.4. By End User
    • 5.3.2. India Non-Clinical Trials Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Study Type
        • 5.3.2.2.2. By Test
        • 5.3.2.2.3. By Therapeutic Area
        • 5.3.2.2.4. By End User
    • 5.3.3. Australia Non-Clinical Trials Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Study Type
        • 5.3.3.2.2. By Test
        • 5.3.3.2.3. By Therapeutic Area
        • 5.3.3.2.4. By End User
    • 5.3.4. Japan Non-Clinical Trials Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Study Type
        • 5.3.4.2.2. By Test
        • 5.3.4.2.3. By Therapeutic Area
        • 5.3.4.2.4. By End User
    • 5.3.5. South Korea Non-Clinical Trials Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Study Type
        • 5.3.5.2.2. By Test
        • 5.3.5.2.3. By Therapeutic Area
        • 5.3.5.2.4. By End User

6. Europe Non-Clinical Trials Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Study Type
    • 6.2.2. By Test
    • 6.2.3. By Therapeutic Area
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Non-Clinical Trials Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Study Type
        • 6.3.1.2.2. By Test
        • 6.3.1.2.3. By Therapeutic Area
        • 6.3.1.2.4. By End User
    • 6.3.2. Germany Non-Clinical Trials Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Study Type
        • 6.3.2.2.2. By Test
        • 6.3.2.2.3. By Therapeutic Area
        • 6.3.2.2.4. By End User
    • 6.3.3. Spain Non-Clinical Trials Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Study Type
        • 6.3.3.2.2. By Test
        • 6.3.3.2.3. By Therapeutic Area
        • 6.3.3.2.4. By End User
    • 6.3.4. Italy Non-Clinical Trials Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Study Type
        • 6.3.4.2.2. By Test
        • 6.3.4.2.3. By Therapeutic Area
        • 6.3.4.2.4. By End User
    • 6.3.5. United Kingdom Non-Clinical Trials Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Study Type
        • 6.3.5.2.2. By Test
        • 6.3.5.2.3. By Therapeutic Area
        • 6.3.5.2.4. By End User

7. North America Non-Clinical Trials Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test
    • 7.2.2. Study Type
    • 7.2.3. By End User
    • 7.2.4. By Therapeutic Area
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Non-Clinical Trials Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Study Type
        • 7.3.1.2.2. By Test
        • 7.3.1.2.3. By Therapeutic Area
        • 7.3.1.2.4. By End User
    • 7.3.2. Mexico Non-Clinical Trials Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Study Type
        • 7.3.2.2.2. By Test
        • 7.3.2.2.3. By Therapeutic Area
        • 7.3.2.2.4. By End User
    • 7.3.3. Canada Non-Clinical Trials Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Study Type
        • 7.3.3.2.2. By Test
        • 7.3.3.2.3. By Therapeutic Area
        • 7.3.3.2.4. By End User

8. South America Non-Clinical Trials Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Study Type
    • 8.2.2. By Test
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Non-Clinical Trials Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Study Type
        • 8.3.1.2.2. By Test
        • 8.3.1.2.3. By Therapeutic Area
        • 8.3.1.2.4. By End User
    • 8.3.2. Argentina Non-Clinical Trials Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Study Type
        • 8.3.2.2.2. By Test
        • 8.3.2.2.3. By Therapeutic Area
        • 8.3.2.2.4. By End User
    • 8.3.3. Colombia Non-Clinical Trials Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Study Type
        • 8.3.3.2.2. By Test
        • 8.3.3.2.3. By Therapeutic Area
        • 8.3.3.2.4. By End User

9. Middle East and Africa Non-Clinical Trials Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Study Type
    • 9.2.2. By Drug Type
    • 9.2.3. By Therapeutic Area
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Non-Clinical Trials Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Study Type
        • 9.3.1.2.2. By Test
        • 9.3.1.2.3. By Therapeutic Area
        • 9.3.1.2.4. By End User
    • 9.3.2. Saudi Arabia Non-Clinical Trials Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Study Type
        • 9.3.2.2.2. By Drug Type
        • 9.3.2.2.3. By Therapeutic Area
        • 9.3.2.2.4. By End User
    • 9.3.3. UAE Non-Clinical Trials Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Study Type
        • 9.3.3.2.2. By Test
        • 9.3.3.2.3. By Therapeutic Area
        • 9.3.3.2.4. By End User

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Non-Clinical Trials Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Labcorp Drug Development
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Charles River Laboratories
  • 14.3. PPD (Pharmaceutical Product Development)
  • 14.4. ICON plc
  • 14.5. Novartis AG
  • 14.6. Merck & Co., Inc.
  • 14.7. AstraZeneca plc
  • 14.8. CMIC HOLDINGS Co., LTD
  • 14.9. ProPharma
  • 14.10.MorphoSys AG

15. Strategic Recommendations

16. About Us & Disclaimer